Clinical and biological diversity of splenic marginal zone lymphoma

Matutes, Estella

doi:10.1586/era.09.91

Cited by 10 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, human splenic MZL is characterized by splenomegaly and lymphocytosis in up to 75% of patients, with bone marrow infiltration in most patients. [2][3][4]13,15 Later development of high-grade multicentric lymphoma was observed in only 1 dog. This dog's high-grade lymphoma was resistant to various chemotherapeutics, and the dog was euthanized 122 days later.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, human splenic MZL is characterized by splenomegaly and lymphocytosis in up to 75% of patients, with bone marrow infiltration in most patients. 2–4,13,15 …”

Section: Discussionmentioning

confidence: 99%

“…In humans, splenectomy is the standard of care for MZL for patients with symptomatic splenomegaly and progressive hematological abnormalities such as lymphocytosis and cytopenias. 4,5,13 Splenectomy is not curative in humans, but yields excellent control of the disease with a median time to progression of 4-5 years. 4,5,14 The role of chemotherapy in humans remains largely unknown, but chemotherapy is used when splenectomy is contraindicated.…”

Section: Discussionmentioning

confidence: 99%

“…4,5,14 The role of chemotherapy in humans remains largely unknown, but chemotherapy is used when splenectomy is contraindicated. [2][3][4][5]13 A prospective study evaluating the use of adjuvant chemotherapy as compared to no chemotherapy for splenectomized dogs with MZL would be necessary to further evaluate the effect of chemotherapy on survival.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

O’Brien

Moore

Vernau

et al. 2013

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Splenic marginal zone lymphoma (MZL) is a form of indolent B-cell lymphoma that is not well characterized in dogs. Hypothesis/Objectives The purpose of this study was to describe clinical characteristics and outcome in dogs with splenic MZL confirmed by histopathology, immunophenotyping, and molecular clonality assessment. We hypothesized that affected dogs would have prolonged survival time with splenectomy alone. Animals Thirty-four dogs were included. Twenty-nine dogs were diagnosed after splenectomy, and 5 dogs were diagnosed at necropsy. Methods Pathology records were searched for dogs with histologically confirmed splenic MZL. Clinical and outcome data were retrospectively collected by medical record review, and prognostic factors were evaluated. Histopathology was reviewed by a board-certified pathologist, and tissue sections were subjected to immunophenotyping and molecular clonality assessment by PCR. Results Immunohistochemistry confirmed a B-cell phenotype for all dogs. Molecular clonality assessment was performed in 33 of 34 dogs, of which 24 had clonal rearrangement of immunoglobulin (Ig) loci, 3 had pseudoclonal rearrangement, and 6 had polyclonal rearrangement. The overall median survival time (MST) for the 29 dogs that underwent splenectomy was 383 days. The MST for 14 of 29 asymptomatic dogs that underwent splenectomy for MZL was 1,153 days as compared to 309 days for 15/29 dogs with clinical signs referable to splenic MZL (P = .018). Lymph node involvement, hemoabdomen, anemia, chemotherapy, and concurrent malignancy did not affect survival outcome. Conclusions and Clinical Importance Dogs diagnosed with splenic MZL can have prolonged survival with splenectomy alone, without the use of adjuvant chemotherapy. Asymptomatic dogs may have a better survival outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In contrast, human splenic MZL is characterized by splenomegaly and lymphocytosis in up to 75% of patients, with bone marrow infiltration in most patients. 2–4,13,15 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

O’Brien

Moore

Vernau

et al. 2013

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…SMZL is considered an indolent B-cell lymphoma as the median overall survival (OS) for SMZL cases is between 8 and 11 years, but clinical presentations remain very heterogeneous [ 6 – 8 ]. Most importantly, it is estimated that 70% of SMZL cases will at some point require treatment for worsening symptoms [ 2 , 9 ], and approximately 30% of SMZL patients will display a more aggressive prognosis with potential for progression to more lethal lymphomas and a decreased overall survival [ 1 , 10 – 14 ]. Due to the limited number of available cases as well as the heterogeneous nature of SMZL, it is very difficult to differentiate indolent and aggressive SMZL cases, resulting in treatment inconsistencies and discrepancies among predicted clinical prognoses.…”

Section: Introductionmentioning

confidence: 99%

Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA

Robinson

Cutucache

2018

Oncotarget

View full text Add to dashboard Cite

Splenic marginal zone lymphoma (SMZL) is a malignancy of mature B-cells that primarily involves the spleen, but can affect peripheral organs as well. Even though SMZL is overall considered an indolent malignancy, the majority of cases will eventually progress to be more aggressive. In recent years, the gene expression profile of SMZL has been characterized in an effort to identify: 1) the etiology of SMZL, 2) biological consequences of SMZL, and 3) putative therapeutic targets. However, due to the vast heterogeneity of the malignancy, no conclusive target(s) have been deciphered. However, the role of miRNA in SMZL, much as it has in chronic lymphocytic leukemia, may serve as a guiding light. As a result, we review the comprehensive expression profiling in SMZL to-date, as well as describe the miRNA (and potential mechanistic roles) that may play a role in SMZL transformation, particularly within the 7q region.

show abstract

Survival outcomes with and without splenectomy in splenic marginal zone lymphoma

Olszewski

2012

American J Hematol

View full text Add to dashboard Cite

Clinical and biological diversity of splenic marginal zone lymphoma

Cited by 10 publications

References 36 publications

Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA

Survival outcomes with and without splenectomy in splenic marginal zone lymphoma

Contact Info

Product

Resources

About